1Vane J R,Botting R M.Mechanism of action of nonsteroidal anti-inflammatory drugs[].The American Journal of Medicine.1998
2Wolfe MM,Lichtenstein DR,Singh G.Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs[].The New England Journal of Medicine.1999
3Paulus HE.FDA Arihritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal anti-inflammatory drugs[].Arthritis and Rheumatism.1985
4Karim A,Tolbert DS,Hunt TL,et al.Celecoxib, a specific COX-2 inhibitor, has no significant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis[].The Journal of Rheumatology.1999
5American Pain Society Quality of Care Committee.Quality improvement guidelines for the treatment of acute pain and cancer pain[].The Journal of The American Medical Association.1995
6Lipsky PE. Abramson SB,Crofford L,et al.The classification of eyclooxygenase inhibitors[].The Journal of Rheumatology.1998
7Singh G.Recent consideration in nonsteroidal anti-inflammatory drug gastropathy[].The American Journal of Medicine.1998
8Vane JR.Inhibition of prostaglandin synthesis as a mechanism of action for asprin-like drugs[].Nature.1971
9Needleman P,Isakson PC.The discovery and function of COX-2[].The Journal of Rheumatology.1997
10Bazan N.,Boffing J,Vane J.New targets in inflammation, inhibitors of COX-2 or adbesion molecules[]..
